COVID-19 Drug Discovery Using Intensive Approaches

Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines a...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2020-04, Vol.21 (8), p.2839
Main Authors: Asai, Ayumu, Konno, Masamitsu, Ozaki, Miyuki, Otsuka, Chihiro, Vecchione, Andrea, Arai, Takahiro, Kitagawa, Toru, Ofusa, Ken, Yabumoto, Masami, Hirotsu, Takaaki, Taniguchi, Masateru, Eguchi, Hidetoshi, Doki, Yuichiro, Ishii, Hideshi
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral Agents - chemistry
Antiviral Agents - therapeutic use
Betacoronavirus
Chemical compounds
China
Clinical trials
Coronaviridae
Coronavirus Infections - drug therapy
Coronaviruses
COVID-19
COVID-19 Drug Treatment
Drug development
Drug Discovery
Drugs
Humans
Infectious diseases
Pandemics
Pharmacology
Pneumonia, Viral - drug therapy
Review
RNA viruses
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Signs and symptoms
Vaccines
Viral infections
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms21082839